Skip to main content
Premium Trial:

Request an Annual Quote

Bionomics Shareholders OK Iliad Acquisition, Green-Light $4.6M Stock Placement

NEW YORK, June 27 (GenomeWeb News) - Australian biotech Bionomics shareholders today approved the company's acquisition of Iliad Chemicals, the company said today. The shareholders also gave the company the green light to raise AU$6 million ($4.6 million).


Bionomics said last month that it planned to acquire the privately held drug-discovery company Iliad Chemicals for AU$9 million. At the time, the company said it had completed an AU$6 million placement, subject to today's shareholder approval, to fund development programs in cancer and central nervous system disorders.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.